These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 19657316

  • 1. Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma.
    Nielsen VG.
    Blood Coagul Fibrinolysis; 2009 Apr; 20(3):191-6. PubMed ID: 19657316
    [Abstract] [Full Text] [Related]

  • 2. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
    Nielsen VG, Steenwyk BL, Gurley WQ.
    J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
    [Abstract] [Full Text] [Related]

  • 3. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
    Nielsen VG, Kirklin JK, George JF.
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
    [Abstract] [Full Text] [Related]

  • 4. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation.
    Nielsen VG.
    Ann Thorac Surg; 2006 May; 81(5):1720-7. PubMed ID: 16631662
    [Abstract] [Full Text] [Related]

  • 5. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
    Nielsen VG.
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
    [Abstract] [Full Text] [Related]

  • 6. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 7. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH, Rijken DC.
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [Abstract] [Full Text] [Related]

  • 8. Carbon monoxide releasing molecule-2 enhances coagulation and attenuates fibrinolysis by two mechanisms: insights gained with colloid dilution.
    Cohen JB, Persaud JM, Malayaman SN, Nielsen VG.
    Blood Coagul Fibrinolysis; 2011 Jan; 22(1):60-6. PubMed ID: 21157300
    [Abstract] [Full Text] [Related]

  • 9. Quantification of the effects of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin on fibrinolysis in normal human plasma.
    Nielsen VG, Ellis TC.
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):29-33. PubMed ID: 17179823
    [Abstract] [Full Text] [Related]

  • 10. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plasmin interactions.
    Nielsen VG.
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):647-56. PubMed ID: 17890952
    [Abstract] [Full Text] [Related]

  • 11. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR, Gardell SJ.
    Thromb Haemost; 1992 Aug 03; 68(2):165-9. PubMed ID: 1412162
    [Abstract] [Full Text] [Related]

  • 12. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation.
    Nielsen VG, Cohen BM, Cohen E.
    Blood Coagul Fibrinolysis; 2006 Jan 03; 17(1):75-81. PubMed ID: 16607085
    [Abstract] [Full Text] [Related]

  • 13. Clot lifespan model analysis of the effects of warfarin on thrombus growth and fibrinolysis: role of contact protein and tissue factor initiation.
    Nielsen VG, Kirklin JK, Holman WL, Steenwyk BL.
    ASAIO J; 2009 Jan 03; 55(1):33-40. PubMed ID: 19092656
    [Abstract] [Full Text] [Related]

  • 14. Carbon monoxide releasing molecule-2 enhances coagulation and diminishes fibrinolytic vulnerability in subjects exposed to warfarin.
    Nielsen VG, Khan ES, Kirklin JK, George JF.
    Thromb Res; 2010 Jul 03; 126(1):68-73. PubMed ID: 20406708
    [Abstract] [Full Text] [Related]

  • 15. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII.
    Nielsen VG, Cohen BM, Cohen E.
    Acta Anaesthesiol Scand; 2005 Feb 03; 49(2):222-31. PubMed ID: 15715625
    [Abstract] [Full Text] [Related]

  • 16. Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity.
    Malayaman SN, Cohen JB, Machovec KA, Bernhardt BE, Arkebauer MR, Nielsen VG.
    Blood Coagul Fibrinolysis; 2011 Jun 03; 22(4):345-8. PubMed ID: 21330914
    [Abstract] [Full Text] [Related]

  • 17. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor.
    Nielsen VG.
    Blood Coagul Fibrinolysis; 2008 Jun 03; 19(4):283-7. PubMed ID: 18469549
    [Abstract] [Full Text] [Related]

  • 18. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
    von dem Borne PA, Cox LM, Bouma BN.
    Blood Coagul Fibrinolysis; 2006 Jun 03; 17(4):251-7. PubMed ID: 16651866
    [Abstract] [Full Text] [Related]

  • 19. The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography.
    Audu P, Nielsen VG, Armstead V, Powell G, Kim J, Kim L, Mehta M.
    Anesth Analg; 2006 Oct 03; 103(4):841-5. PubMed ID: 17000790
    [Abstract] [Full Text] [Related]

  • 20. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma.
    Nielsen VG.
    J Heart Lung Transplant; 2006 Nov 03; 25(11):1344-52. PubMed ID: 17097499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.